Galectin therapeutics inc (GALT)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss

-14,475

-13,294

-11,207

-11,175

-12,017

-13,900

-13,232

-14,888

-15,556

-16,235

-18,444

-18,562

-19,573

-21,436

-21,516

-22,877

-22,001

-20,027

-19,087

-16,718

-15,504

-15,788

0

0

0

Adjustments to reconcile net loss to net cash flows from operating activities:
Payment of preferred stock dividends

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Payment of preferred stock dividends

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Depreciation and amortization

-

-

-

-

-

-

-

-

-

1

3

5

7

7

6

6

6

7

8

9

10

10

0

0

0

Stock-based compensation expense

1,701

1,683

2,421

2,670

3,670

4,445

3,565

3,132

1,958

1,101

1,307

1,453

1,586

2,479

2,874

3,291

3,688

3,400

3,326

3,410

3,357

4,070

0

0

0

Amortization of right to use lease asset

34

35

0

0

0

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Issuance of common stock for services

-

-

-

-

-

12

17

25

26

33

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Loss from equity method investment in Galectin Sciences LLC

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-130

-400

0

0

0

Non-cash interest expense

87

87

145

210

274

336

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Changes in operating assets and liabilities:
Prepaid expenses and other assets

46

356

114

484

199

-19

-1

-4

-10

-8

0

-37

-72

-122

-130

-66

-186

21

93

218

460

335

0

0

0

Accounts payable and accrued expenses

369

997

-368

-43

-1,295

-1,091

-2,695

-2,076

-2,079

-812

254

-125

1,112

2,419

2,361

1,729

1,959

-342

341

-239

-651

-783

0

0

0

Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-16,782

-16,409

-16,145

-17,785

-16,162

-16,983

-15,495

-13,693

-13,118

-12,426

0

0

0

Equity method investment in Galectin Sciences LLC

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

400

0

0

0

Net cash from operating activities

-11,935

-10,848

-9,096

-9,198

-9,947

-10,179

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

CASH FLOWS FROM INVESTING ACTIVITIES:
Net cash from investing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

-400

0

0

0

CASH FLOWS FROM FINANCING ACTIVITIES:
Net proceeds from issuance of common stock and warrants

48,685

50,469

49,691

50,744

12,931

15,379

15,254

14,992

5,889

3,583

0

0

0

-

-

-

-

13,701

5,672

5,691

5,691

29,337

0

0

0

Net proceeds from exercise of common stock warrants and options

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2,128

0

0

0

Net cash provided by financing activities

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

13,701

5,613

5,632

5,873

31,465

0

0

0

Net cash from financing activities

48,291

50,075

49,297

50,744

12,931

15,379

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

NET DECREASE IN CASH AND CASH EQUIVALENTS

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

NET INCREASE IN CASH AND CASH EQUIVALENTS

-

-

-

-

-

-

-

1,370

-9,656

-12,309

-9,101

-8,876

-8,712

-10,484

-5,260

-8,359

-6,993

-3,282

-9,882

-8,061

-7,245

18,639

0

0

0

NONCASH FINANCING ACTIVITIES:
Payment of preferred stock dividends in common stock

0

-

-

-

-

915

1,253

1,213

1,246

1,232

1,102

912

861

742

773

850

828

868

809

876

891

943

0

0

0